 |
| Philip Hampton |
It's official: GlaxoSmithKline ($GSK) tapped Royal Bank of Scotland chair Philip Hampton to take the reins as chairman. The choice comes as increasingly restive shareholders call for change at the drugmaker, plagued by corruption scandals and suffering from competition to its megablockbuster respiratory drug Advair. He'll join GSK's board Jan. 1, become deputy chair in April and move into Chairman Christopher Gent's seat in September 2015. Report